Trader notes, earnings previews, Confluences, weekly digests and roundups — long-form analysis grounded in ORTEX short interest, options flow and analyst data.
All articles — 31759 total
MMED is the week's standout mover. Short interest jumped to 103% of free float, up from 79% seven days ago. That 24-point surge, the biggest weekly increase among stocks above $500M market cap, comes as MiniMed carries…
The biggest story this week is the scale of equity buying. ETF investors pushed $113B net into equity funds in just seven days. That flow imbalance sits at 74, well above the neutral mark of 50. Over three months the…
Q3 bank reporting season takes centre stage. UnitedHealth Group opens Monday's proceedings, with Johnson & Johnson following Tuesday before the bell. The bank roll-call runs Wednesday through Friday: Bank of America,…
Options activity is skewing bearish across large-caps this week. Earnings from major US banks are the dominant catalyst. Bank of America, Truist Financial and The Bank of New York Mellon all report Q3 results this…
Q3 bank reporting season shifts into top gear this week, with a string of major US financials set to post results alongside healthcare and European names. UnitedHealth Group fires the starting gun on Monday, reporting…
The Fidelity U.S. Value ETF (FCUV), listed on the TSX, enters the week with a quiet but notable tension: short interest has been climbing steadily for a month while the ETF itself continues to drift higher. Short…
Estée Lauder EL drew the most notable bearish call of the session. Consensus downgrades pushed the stock lower on the board. The average target price holds at $107.34, but the sell-side shifted a rating from hold to…
Voyager Technologies enters the week to November earnings with a sharp contradiction at its core: short sellers have added steadily to positions through a brutal one-month decline, yet the borrow market remains…
BigBear.ai heads into its October 27 earnings with one of the most heavily shorted books in the small-cap AI universe, a lending market that tightened sharply this week, and options traders more bullish than the…
ImmunityBio now carries two distinct countdowns: November 6 earnings and an October 30 rank date that could trigger a Russell index reshuffle, giving the stock a mechanical catalyst layer that most biotech notes this…
Clover Health Investments enters the final stretch before its November 4 earnings with short sellers adding to positions for a second consecutive session, the stock up 9.4% on the week to $4.79, and retail attention…
The Trade Desk goes into its October 19 earnings report carrying a newly diminished index status, a short position that remains near a fifth of its free float, and options traders running at the most bullish extreme of…
HealthEquity enters the final stretch before its December earnings with a subtle but consistent shift in positioning: short sellers have been adding exposure for six weeks, options markets have turned more defensive,…
MARA Holdings carries 27.6% short interest into its November 6 earnings date, with the stock down 14% on the week and the sector selling off broadly, yet options traders are positioned more bullishly than the headline…
Brookfield Infrastructure Partners enters its October 14 quarterly release with one structural fact towering over everything else: its parent, Brookfield Corporation, holds a 31.5% stake on a Schedule 13D, and that…
RELX heads into its October 23 results with a sharp rally behind it and a wide gap between today's price and where analysts think it belongs. The stock climbed 7.6% on the week to close at 270p, adding a further 4.8%…
MOL has added 4.2% this week to close at HUF 5,055, a quiet consolidation that masks a genuine tension: the borrow market is tightening at the same time the insider register is sending conflicting signals, with Q3…
BOT enters the week in a curious position: short sellers have quietly reduced their footprint over the past month, yet borrowing costs remain high and the company's most recent insider action was a near-$10 million…
PS has climbed 31% in a month, yet the borrow market is pricing extreme difficulty in shorting the stock, analysts are cutting to Sell, and options traders are piling into downside protection at a rate not seen in over…
CDNL has dropped 45% over the past month to $21.12, yet analysts hold five buy ratings with a mean target of $54.25, and a cluster of insiders spent nearly $10 million buying shares in August when the stock was trading…
